Medi Caps

Which are the latest news on Medi Caps?

Why is Medi Caps Ltd falling/rising?

As of 05-Sep, Medi Caps Ltd's stock price is at Rs 25.85, reflecting a 5.38% increase today. Despite recent declines over longer periods, today's performance indicates a positive shift in investor sentiment and increased participation.

As of 05-Sep, Medi Caps Ltd's stock price is rising, currently at Rs 25.85, which reflects an increase of 1.32 or 5.38%. This upward movement is notable as the stock opened with a gain of 5.38% today and has maintained this price level throughout the trading session. Additionally, the stock has outperformed its sector by 5.83%, indicating strong relative performance.<BR><BR>Investor participation appears to be increasing, as evidenced by a rise in delivery volume of 2.75k on September 3, which is up by 3% compared to the 5-day average. This suggests that more investors are willing to hold the stock, contributing to the upward price momentum.<BR><BR>However, it is important to note that despite today's rise, Medi Caps Ltd has experienced significant declines over longer periods, including a year-to-date drop of 17.23% and a one-year decline of 36.33%. The stock is currently trading below its moving averages across various time frames, which typically indicates a bearish trend. Nonetheless, the immediate performance today shows a positive shift in sentiment among investors.

Who are in the management team of Medi Caps?

The management team of Medi Caps includes R C Mittal (Chairman), Alok K Garg (Managing Director), and several non-executive and independent directors, including Pramod Fatehpuria, Ashok Omprakash Agrawal, Kusum Mittal, Dharmendra Solanki, and Gajendra Singh, along with Company Secretary Abhishek Kumar. They oversee the company's operations and strategic direction.

The management team of Medi Caps includes the following individuals:<BR><BR>1. R C Mittal - Chairman (Non-Executive)<BR>2. Alok K Garg - Managing Director<BR>3. Pramod Fatehpuria - Non-Executive & Independent Director<BR>4. Ashok Omprakash Agrawal - Non-Executive & Independent Director<BR>5. Kusum Mittal - Non-Executive Director<BR>6. Dharmendra Solanki - Independent Director<BR>7. Abhishek Kumar - Company Secretary & Compliance Officer<BR>8. Gajendra Singh - Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

What does Medi Caps do?

Medi Caps Ltd manufactures empty hard gelatine capsules for the pharmaceuticals and biotechnology industry. As of June 2026, it reported net sales of 3 Cr and a net loss of 2 Cr, with a market cap of INR 31 Cr.

Overview:<BR>Medi Caps Ltd is a company that manufactures empty hard gelatine capsules for the pharmaceuticals and biotechnology industry, operating within the micro cap market.<BR><BR>History:<BR>Medi Caps Limited was incorporated in August 1983 as a Private Limited Company and converted into a Public Limited Company in March 1986. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 3 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: -2 Cr (Quarterly Results - Jun 2026) <BR>Market cap: INR 31 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.21 <BR>Return on Equity: -2.72% <BR>Price to Book: 0.28<BR><BR>Contact Details:<BR>Address: Mhow-Neemuch Road, Sector - I Pithampur Madhya Pradesh : 454775 <BR>Tel: 91-07292-424242 <BR>Email: investors@medicaps.com <BR>Website: http://www.medicaps.com

Who are the peers of the Medi Caps?

Medi Caps' peers include Vista Pharma, Sandu Pharma, Lasa Supergeneri, Guj. Terce Labs, Cian Healthcare, Welcure Drugs, Venmax Drugs, Ishita Drugs, and Medicamen Organ. Medi Caps has a good capital structure and a 1-year return of -35.44%, better than Welcure Drugs but worse than Cian Healthcare, which has the highest return at 252.28%.

Peers: The peers of Medi Caps are Vista Pharma., Sandu Pharma., Lasa Supergeneri, Guj. Terce Labs., Cian Healthcare, Welcure Drugs, Venmax Drugs, Ishita Drugs, and Medicamen Organ.<BR><BR>Quality Snapshot: Below Average management risk is observed at Vista Pharma., Lasa Supergeneri, Guj. Terce Labs., Cian Healthcare, Venmax Drugs, Medicamen Organ., and the rest. Average management risk is found at Sandu Pharma. and Welcure Drugs. Medi Caps has a Good capital structure, along with Sandu Pharma., Welcure Drugs, and Ishita Drugs, while the rest have Below Average or Average capital structures. Growth is Below Average for Vista Pharma., Lasa Supergeneri, Guj. Terce Labs., Medi Caps, Cian Healthcare, and Venmax Drugs, while Average growth is noted at Sandu Pharma. and Guj. Terce Labs., with Good growth at Sandu Pharma. and Welcure Drugs.<BR><BR>Return Snapshot: Cian Healthcare has the highest 1-year return at 252.28%, while Welcure Drugs has the lowest at -72.73%. Medi Caps' 1-year return of -35.44% is better than Welcure Drugs but worse than Cian Healthcare. Additionally, the six-month returns are negative for Welcure Drugs, Venmax Drugs, and Medicamen Organ.

How big is Medi Caps?

As of 31st August, Medi Caps Ltd has a market capitalization of 31.00 Cr, with net sales of 12.56 Cr and a net loss of 1.78 Cr over the latest four quarters. Shareholder's funds were 111.61 Cr, and total assets were 115.46 Cr as of March 2026.

As of 31st August, Medi Caps Ltd has a market capitalization of 31.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Medi Caps reported Net Sales of 12.56 Cr. However, the company experienced a loss of 1.78 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2026, where Shareholder's Funds amounted to 111.61 Cr and Total Assets were reported at 115.46 Cr.

Should I buy, sell or hold Medi Caps Ltd?

Are Medi Caps Ltd latest results good or bad?

Medi Caps Ltd's latest results are concerning, showing a net profit of ₹3.04 crores mainly due to one-time income, while revenues plummeted by 50.50% year-on-year and operating margins are deeply negative at -60.23%. Overall, the company's fundamentals indicate significant operational challenges and a distressed state, warranting caution for investors.

Medi Caps Ltd's latest results present a mixed picture that leans towards the negative. While the company reported a net profit of ₹3.04 crores for Q4 FY26, which is a significant increase of 76.74% year-on-year, this profit is largely misleading. It was primarily driven by exceptional other income of ₹5.59 crores, which accounted for 184.49% of profit before tax. Without this one-time income, the company would have faced substantial operational losses of ₹2.06 crores.<BR><BR>On the revenue front, Medi Caps experienced a severe decline, with revenues falling to ₹3.45 crores, marking a 50.50% year-on-year decrease and a 19.77% drop from the previous quarter. This decline indicates significant challenges in the company's core operations and market position.<BR><BR>Additionally, the operating margin is deeply negative at -60.23%, reflecting an unsustainable business model. The company's return on equity (ROE) is also alarmingly low at 1.46%, with a recent quarterly ROE of -4.84%, suggesting that it is actively destroying shareholder value.<BR><BR>Overall, while the reported profit figure may seem positive at first glance, the underlying operational performance is concerning, with significant revenue contraction and unsustainable margins. This situation raises serious questions about the company's future viability and operational health. Investors should approach Medi Caps with caution, as the fundamentals indicate a distressed state rather than a recovery.

When is the next results date for Medi Caps Ltd?

The next results date for Medi Caps Ltd is 21 May 2026.

The next results date for Medi Caps Ltd is scheduled for 21 May 2026.

How has been the historical performance of Medi Caps?

Medi Caps has experienced a significant decline in net sales and profitability, with net sales dropping from 69.87 Cr in Mar'22 to 25.47 Cr in Mar'25, resulting in operating losses and negative profits over the same period. The company's total assets also decreased slightly, reflecting ongoing financial challenges.

Answer:<BR>The historical performance of Medi Caps shows a significant decline in net sales and profitability over the years, culminating in losses in the most recent fiscal year.<BR><BR>Breakdown:<BR>Medi Caps experienced a downward trend in net sales, dropping from 69.87 Cr in Mar'22 to 25.47 Cr in Mar'25. This decline is mirrored in total operating income, which also fell from 69.87 Cr in Mar'22 to 25.47 Cr in Mar'25. The company's total expenditure, excluding depreciation, decreased from 59.92 Cr in Mar'22 to 27.30 Cr in Mar'25, yet this was not sufficient to prevent operating losses, with operating profit (PBDIT) declining from 11.86 Cr in Mar'22 to -1.83 Cr in Mar'25. Profit before tax also turned negative, moving from 10.06 Cr in Mar'22 to -0.84 Cr in Mar'25, and profit after tax followed suit, decreasing from 10.04 Cr in Mar'22 to -0.57 Cr in Mar'25. The company's cash flow from operating activities showed a slight decrease from 7.00 Cr in Mar'22 to 5.00 Cr in Mar'25, while total assets slightly decreased from 130.35 Cr in Mar'22 to 125.42 Cr in Mar'25. Overall, Medi Caps has faced significant challenges, reflected in its declining sales, profitability, and asset values over the past few years.

Is Medi Caps overvalued or undervalued?

As of February 9, 2024, Medi Caps is considered undervalued with a low Price to Book Value of 0.44 and a negative PE Ratio of -53.55, despite its recent stock performance showing a YTD return of -10.77%, indicating a significant shift from a very expensive to a risky valuation grade compared to peers like Sun Pharma and Divi's Lab.

As of 9 February 2024, Medi Caps has moved from a valuation grade of very expensive to risky, indicating a significant shift in its financial outlook. The company is currently assessed as undervalued, primarily due to its low Price to Book Value of 0.44 and a negative PE Ratio of -53.55. Other notable ratios include an EV to EBITDA of -13.35 and a ROCE of -3.85%, which further highlight the company's struggles.<BR><BR>When compared to its peers, Medi Caps stands out with a PEG Ratio of 0.00, while competitors like Sun Pharma and Divi's Lab have significantly higher PE Ratios of 35.25 and 79.33, respectively. This stark contrast suggests that Medi Caps may be undervalued relative to its peers, despite its current financial challenges. Additionally, the company's recent stock performance shows a YTD return of -10.77%, underperforming against the Sensex, which returned 5.62% in the same period.

What is the technical trend for Medi Caps?

As of June 4, 2025, Medi Caps shows a mildly bearish technical trend, with mixed signals from the MACD and bearish indicators from moving averages and Bollinger Bands.

As of 4 June 2025, the technical trend for Medi Caps has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD is mildly bearish, indicating mixed signals. The Bollinger Bands are bearish in both weekly and monthly time frames, and daily moving averages are also bearish. The KST shows a mildly bullish stance on the weekly chart but is mildly bearish on the monthly. There are no clear trends indicated by Dow Theory in either time frame. Overall, the current technical stance is mildly bearish, driven primarily by the bearish signals from moving averages and Bollinger Bands, despite some mildly bullish indicators in the MACD and KST on the weekly chart.

Who are the top shareholders of the Medi Caps?

The top shareholders of Medi Caps include Alok K Garg, who holds 25.87%, and individual investors with a combined 44.57%. The highest public shareholder is Sangeetha S at 5.57%, with no pledged promoter holdings and minimal mutual fund or foreign institutional investor involvement.

The top shareholders of Medi Caps include the promoters, with Alok K Garg holding the highest stake at 25.87%. Individual investors collectively hold 44.57% of the shares, while the highest public shareholder is Sangeetha S, who owns 5.57%. Additionally, there are no pledged promoter holdings, and the company has minimal mutual fund and foreign institutional investor involvement.

What is the bonus history of the Medi Caps?

Medi Caps issued a 3:1 bonus in 2013, where shareholders received three additional shares for each share held. The ex-date was March 19, 2013, and the record date was March 20, 2013.

Medi Caps has a bonus history that includes a significant bonus issue announced in 2013. Specifically, the company issued a 3:1 bonus, which means that for every one share held, shareholders received three additional shares. The ex-date for this bonus was March 19, 2013, and the record date was March 20, 2013. This was the latest recorded bonus action for the company.

Has Medi Caps declared dividend?

Medi Caps Ltd has declared a 15% dividend, amounting to 0.3800 per share, but the dividend yield is 0% as no recent dividends have been paid out. Total returns have varied significantly, with a 333.3% increase over the past 5 years despite negative returns in shorter periods.

Medi Caps Ltd has declared a 15% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 15%<BR>- Amount per share: 0.3800<BR>- Ex-date: 20 Sep 12<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -17.38%, the dividend return was 0%, resulting in a total return of -17.38%.<BR><BR>In the 1-year period, the price return was -5.29%, the dividend return was 0%, resulting in a total return of -5.29%.<BR><BR>In the 2-year period, the price return was 18.03%, the dividend return was 0%, resulting in a total return of 18.03%.<BR><BR>In the 3-year period, the price return was -13.68%, the dividend return was 0%, resulting in a total return of -13.68%.<BR><BR>In the 4-year period, the price return was -7.57%, the dividend return was 0%, resulting in a total return of -7.57%.<BR><BR>In the 5-year period, the price return was 333.3%, the dividend return was 0%, resulting in a total return of 333.3%.<BR><BR>Overall, while Medi Caps has declared a dividend, the dividend yield remains at 0%, indicating no recent dividends have been paid out. The total returns show significant volatility, with a notable increase over the 5-year period despite negative returns in shorter time frames.